{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:09:56Z","timestamp":1787008196331,"version":"build-2736575974"},"reference-count":32,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Studies investigating the safety and efficacy of automated insulin delivery (AID) systems in people with cystic fibrosis-related diabetes are limited. There are no published studies investigating the tubeless Omnipod 5 (OP5) AID system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This dual-center retrospective cohort study compared 14 days of baseline continuous glucose monitoring (CGM) data with days 1\u201390 and 91\u2013180 post-OP5 initiation. Multivariable mixed-effects linear regression models were used to assess changes in glycemic metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 26 individuals with sufficient data initiating OP5, 65% were female, with a median age of 27.3 years and median diabetes duration of 10.9 years. Six (23%) had a history of solid organ transplant, and 2 (8%) were receiving enteral tube feeds. Participants transitioned to OP5 from multiple daily injections (54%), prior Omnipod generation (31%), or another AID system (15%). CGM time in range (70\u2013180 mg\/dL) increased from 54% (95% confidence interval [CI]: 45.0, 63.0) to 64% (95% CI: 57, 71.8,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) during the first 90 days and to 62.7% (95% CI: 54.9, 70.5,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) during 91\u2013180 days. Time above range (TAR) 181\u2013250 mg\/dL and TAR &gt;250 mg\/dL improved at 1\u201390 days and 91\u2013180 days compared with baseline (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001 and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002, respectively). There were no significant changes in time below range (54\u201369 mg\/dL, &lt;54 mg\/dL) or coefficient of variation. Two individuals discontinued OP5 within 14 days due to persistent hypoglycemia. One adult experienced a hypoglycemic seizure after 3 months of use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Use of the OP5 system in youth and adults with CFRD led to significant improvements in multiples measures of hyperglycemia without a change in CGM-measured hypoglycemia over a 6-month period, although patient experience with hypoglycemia may limit sustained use. Given the unique comorbidities and pathophysiology of CFRD, these results emphasize the need for future studies to investigate the safety and efficacy of AID devices in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2025.0075","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:47:23Z","timestamp":1746838043000},"page":"711-718","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-9871","authenticated-orcid":false,"given":"Kevin J.","family":"Scully","sequence":"first","affiliation":[{"name":"Hasbro Children\u2019s Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Reed","sequence":"additional","affiliation":[{"name":"Division of Endocrinology &amp; Diabetes, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Douvas","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-9774","authenticated-orcid":false,"given":"Brynn E.","family":"Marks","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA."},{"name":"Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"Cystic Fibrosis Foundation. 2023 Patient Registry Annual Data Report [Internet]. Bethesda Maryland; 2023. Available from: https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24307"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.12.016"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0576OC"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2017-0005"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107845"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2020.03.014"},{"key":"e_1_3_5_9_2","doi-asserted-by":"crossref","unstructured":"Scully KJ Marks BE Putman MS. Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia. 2024. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38995399\/","DOI":"10.1007\/s00125-024-06223-3"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12732"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.03.007"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-0504"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16143"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0055"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1228153"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0354"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1411"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0172"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0337"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0388"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0578"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12014"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.07.006"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.004"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0194-7"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12470"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac034"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0864"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2008.12.001"},{"issue":"3","key":"e_1_3_5_30_2","first-page":"100","article-title":"Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes","volume":"1","author":"Millington K","year":"2014","unstructured":"Millington K, , Miller V, , Rubenstein RC, , Kelly A. Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes. J Clin Transl Endocrinol, 2014; 1(3):100\u2013107.","journal-title":"J Clin Transl Endocrinol"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0239"},{"key":"e_1_3_5_32_2","unstructured":"Marks B Kilberg M Aliaj E et al. Perceptions of diabetes technology in CFRD. In: North American Cystic Fibrosis Conference. Phoenix; 2020."},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12158"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2025.0075","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2025.0075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2025.0075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:19Z","timestamp":1777400119000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2025.0075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1089\/dia.2025.0075"],"URL":"https:\/\/doi.org\/10.1089\/dia.2025.0075","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}